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Abstract
Medication-assisted treatment (MAT) is underutilized in the treatment of drug-dependent, criminal
justice populations. This study surveyed criminal justice agencies affiliated with the Criminal
Justice Drug Abuse Treatment Studies (CJ-DATS) to assess use of MAT and factors influencing
use of MAT. A convenience sample (N=50) of criminal justice agency respondents (e.g., jails,
prisons, parole/probation, and drug courts) completed a survey on MAT practices and attitudes.
Pregnant women and individuals experiencing withdrawal were most likely to receive MAT for
opiate dependence in jail or prison, while those re-entering the community from jail or prison were
the least likely to receive MAT. Factors influencing use of MAT included criminal justice
preferences for drug-free treatment, limited knowledge of the benefits of MAT, security concerns,
regulations prohibiting use of MAT for certain agencies, and lack of qualified medical staff.
Differences across agency type in the factors influencing use and perceptions of MAT were also
examined.
MAT use is largely limited to detoxification and maintenance of pregnant women in criminal
justice settings. Use of MAT during the community reentry period is minimal. Addressing
inadequate knowledge and negative attitudes about MAT may increase its adoption, but better
linkages to community pharmacotherapy during the reentry period might overcome other issues,
including security, liability, staffing and regulatory concerns. The CJ-DATS collaborative MAT
implementation study to address inadequate knowledge, attitudes and linkage will be described.
Introduction
Medication assisted therapy (MAT) is underutilized in the treatment of alcohol- or opioid-
dependent, criminal justice populations(1–7) despite substantial evidence of its effectiveness
in reducing opioid and alcohol use,(8,9) criminal behavior and arrest,(10–13) and HIV risk
behavior.(14,15) MAT here refers to the addition of pharmacotherapy to traditional
substance abuse counseling in order to attenuate withdrawal symptoms, craving and/or the
reinforcing euphoria resulting from alcohol or drug use. Opioid agonist treatment, for
example, is rare in criminal justice settings in the United States despite widespread
experience in correctional facilities throughout the world (16,17) and expert consensus
recommendations calling for its expansion.(18–20) National concern over the drug-crime
relationship during the past 25 years has led to the predominance of criminal justice
sanctions in lieu of therapeutic approaches like MAT, and this in turn has resulted in a vast
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expansion of the drug-involved correctional population.(21,22) The potential role of MAT
for criminal justice populations is particularly germane today as numerous drug-involved
inmates return to the community, and state budget crises provide impetus for evidence-based
interventions like MAT to reduce the costs of rearrests and re-incarceration as well as the
societal, human and health care costs associated with chronic substance dependence.
Increasing adoption and implementation of evidence-based treatments such as MAT in
criminal justice settings is an overarching goal for the Criminal Justice Drug Abuse
Treatment Studies (CJ-DATS). CJ-DATS is a national research program funded by the
National Institute on Drug Abuse (NIDA). It includes ten Research Centers, their criminal
justice partner organizations, and NIDA scientists. Many of the program’s key questions
reflect the need to understand organizational and systems issues that can facilitate or hinder
implementation of effective drug treatment and other services for criminal justice
populations. Particular interests include how agencies, sites or programs adopt and
implement evidence-based practices across different stages of criminal justice processing, as
well as how the implementation of evidence-based programs and practices can be improved
to yield better client outcomes through increased access to and utilization of services. In
preparation for the design of a multisite implementation trial, the MAT Working Group of
CJ-DATS administered a preliminary planning survey to understand the availability of, need
and readiness for, and barriers to MAT among partnering criminal justice agencies.
Method
Study Population
Data were collected on MAT policies and practices from 50 agencies located in 16 different
locales within the United States, including 14 states, one federal district, and one
unincorporated territory. Criminal justice agencies were comprised of four types: 18 jails, 12
prison or unified prison/jail systems, 12 probation or parole or unified probation/parole
departments, and 8 drug courts. All 50 agencies dealt primarily with adult populations.
Survey Development and Administration
The survey was developed through a consensus- based approach, drawing on the expertise
of our working group and prior correctional surveys.(2,3) The survey was administered in
August – October of 2009 to a convenience sample of criminal justice officials representing
different criminal justice agencies working in partnership with the 10 CJ-DATS research
centers. Investigators identified appropriate respondents (e.g. agency Administrators,
Superintendents, Medical Directors) from CJ partners in jail, prison, probation, parole, and
drug court settings. Some respondents completed the survey independently, while for others,
telephone or in-person interviews were conducted. All research centers received either IRB
exemption or expedited approval for this survey.
Survey Description
Items asked respondents to fill-in the percentages of the agency’s population with opiate or
alcohol dependence, as well as to check boxes to identify the populations provided with
MAT (e.g. individuals experiencing opiate withdrawal, infected with HIV, receiving MAT
in the community, and pregnant women) and the specific medications provided.
Respondents were also asked to indicate whether it would be possible to introduce or expand
use of MAT for opiate addiction and alcohol (Yes/No response format). Additionally,
respondents were asked to rate a series of 15 factors that might influence agency use of
medication (e.g. administrative opposition, security concerns, liability issues, cost concerns)
using a Likert-type scale where a rating of 0 indicated the factor was “Not important” and a
rating of 5 indicated the factor was “Very important”. Open ended questions asked
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respondents to elaborate on factors rated 4 or 5. Finally, using a Likert-type scale where 0
represented “Not at all Likely” and 5 indicated “Very Likely”, respondents were asked to
indicate the likelihood that the agency would introduce or expand MAT in the next 2 years.
Analysis
Data analyses were conducted using SAS software (version 9.2). Fisher’s exact test and
ANOVA were used to compare current practices and descriptive data among the different
types of criminal justice agencies. T-tests and logistic regression were used to compare
agencies that currently provide MAT for maintenance with agencies that do not. Multiple
regression analysis was used to examine the relationship between factors perceived to
influence agency use of MAT and the likelihood of introducing or expanding MAT
practices.
Results
Sites varied dramatically in the reported prevalence of opioid dependence (median, 18%,
interquartile range 8%–50%) and alcohol dependence (median, 33%, interquartile range
15%–63%) across sites, but these rates did not significantly vary by agency type. Of 18 jails,
15 (83%) of jails and 10 (83%) of 12 prisons reported providing MAT for opiate or alcohol
dependence in a limited capacity [e.g., detoxification, administration to pregnant women
only], compared with 3 (37.5%) of 8 Drug Courts and 2 (17%) of 12 Probation/Parole
agencies (Table 1). Overall, methadone was the most commonly used medication (25 of 50
agencies), followed by clonidine (20 of 50 agencies), with buprenorphine (5 agencies, 10%)
and naltrexone (1 agency, 2%) rarely provided.
Jails were the agency most likely to provide MAT, including clonidine, for opiate
detoxification (15 [83%] of 18) followed by prisons (8 [67%] of 12) but only nine (50%) of
the jails and six prisons (50%) provide methadone or buprenorphine for opiate
detoxification. Regarding opiate maintenance, 9 of 18 jails reported providing methadone
for pregnant women (none provided buprenorphine); and five (28%) provided methadone or
buprenorphine for persons already taking that medication. Regarding opiate maintenance in
prison, 9 of 12 prisons or unified jail/prison agencies reported providing methadone or
buprenorphine for pregnant women, three (25%) for persons already taking methadone
(overlapping with those who treat pregnant women), and only one of 12 prisons provided
methadone maintenance for persons not already on methadone. One prison reported
providing buprenorphine maintenance to persons switching from methadone, and one prison
reported providing naltrexone for persons already taking naltrexone.
Probation/Parole agencies were least likely to provide MAT for either detoxification (0) or
maintenance (1 of 12, 8%). Provision of MAT was also rare for individuals who are leaving
a criminal justice agency (e.g. leaving prison or ending probation), with only 12% of
respondents (5 jails, 1 prison) indicating this practice. Of the 30 criminal justice agencies
that provided MAT, 22 (73%) indicated that they were also responsible for funding those
MAT services. Jails and prisons were significantly more likely to fund MAT than drug
courts or probation/parole agencies; only 2 of 12 probation/parole sites provide MAT, with
just one responsible for funding.
Respondents rated the importance of fifteen factors thought to influence agency use of MAT
(Table 2). The top six factors were: 1) Security concerns, 2) MAT is offered by community
treatment programs, 3) Agency favors drug-free treatment over MAT, 4) Concerns about
liability issues, 5) State or local regulations prohibit us from prescribing medications, and 6)
Do not know of evidence of clinical effectiveness for criminal justice populations.
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There were significant differences between agency types. Agency preference for drug free
treatment varied significantly by agency type (F = 5.57, p = .003). Post-hoc comparisons
indicated that prisons tended to cite preference for drug free treatment as a greater factor in
the use of MAT than drug courts (p = .001), jails (p = .08) and probation/parole agencies (p
= .10). The rating of security concerns also differed significantly by agency type (F = 3.8, p
= .02). Post-hoc comparisons indicated that prisons rated security concerns as a greater
factor in use of MAT than probation/parole (p = .02) or drug courts (p = .08). Respondents
were more likely to indicate their belief that jails as compared to than the other three agency
types were prohibited from prescribing medications by state or local regulations (F = 2.4, p
= .09). Drug courts and probation/parole agencies tended to cite lack of qualified medical
staff more so than jails and prisons (F = 2.7, p = .06).
Data from these fifteen factors were also examined by whether or not the agency currently
provides any MAT for maintenance (Table 3). Lack of qualified staff (F = 15.22, p = .0003),
inadequate information (F = 7.10, p = .01), staff objections (F = 6.71, p = .01) and liability
concerns (F = 3.95, p = .05) were rated as significantly more important factors for agencies
not providing MAT for maintenance than for those agencies that provide MAT maintenance.
Agencies that currently provide MAT for maintenance also tended toward lower
endorsement of the perception that “MAT just substitutes one drug for another” (F = 2.90, p
= .10), and that “opiate dependence is not a common problem within the agency” (F = 3.30,
p = .08). Controlling for agency type, independent correlates of the current provision of
MAT for maintenance were lack of qualified staff (χ2 = 5.01, AOR = .63 (.42 – .94), p= .03)
and staff objections to the use of MAT (χ2 = 4.54, AOR = .62 (.40 – .96), p= .03) in a
stepwise multiple logistic regression analysis.
In their open-ended remarks, some prison officials commented that MAT was impractical
because prisoners are typically “clean” by the time they arrive at prison. Some jail officials
agreed that starting MAT in jail was impractical because jail stays are often very short but,
on the other hand, inmates are in withdrawal when they arrive. Remarks on regulatory
concerns indicated that community agencies were often relied on for MAT because of
regulation barriers which require special licensing for the administration of some MAT
medications. Regarding security, comments centered abound concerns about possible
diversion and inmates waiting in line for daily MAT administration. Liability concerns also
focused on possible diversion and overdose. Respondents noted that agency lack of
knowledge of MAT as an evidence-based practice occurred at various levels of the
organization. Some described it as occurring agency-wide, while others depicted it at the
medical staff or officer level. Funding-related comments cited the current budget climate, or,
in the case of some community corrections agencies, the agency does not pay for any
medical services.
Respondents were asked to indicate if it would be possible to introduce or expand MAT if
evidence were available showing that MAT improved criminal justice outcomes. Of the 20
sites that do not currently provide MAT, 70% said it would be possible to introduce
methadone, 70% buprenorphine, and 65% naltrexone. Sites that currently provided MAT
(n=30) expressed similar interest with 63% indicating they would consider expanding
methadone, 63% buprenorphine and 63% naltrexone. Overall, there were no significant
differences between agencies with regards to types of MAT that might be possible to
introduce or expand, or the likelihood of doing so in the next 2 years (Table 4).
Stepwise linear regression analysis was performed to examine the relationship between
factors thought to influence agency use of MAT and the likelihood of expanding/introducing
MAT in the next 2 years while controlling for agency type and current MAT use for
maintenance. Only inadequate information about MAT in the agency (β= .46) was
Friedmann et al. Page 4
Subst Abus. Author manuscript; available in PMC 2013 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
independently related to a higher likelihood of expanding or/introducing MAT (R2 = .35, F
= 6.57 p = .001).
Discussion
Almost three-quarters of the jails and prisons surveyed provide opioid pharmacotherapy for
pregnant inmates and 60% use it for the management of opioid withdrawal. National surveys
of state and federal correctional systems have noted that approximately half use methadone,
predominately for pregnant inmates, short-term detoxification or chronic pain.(2,3) Based on
this availability, infrastructure appears to exist in many jails and prisons that might be
expanded to serve other alcohol- and opioid-dependent criminal justice populations.(23) As
in other studies,(3) current findings suggest that negative attitudes about MAT, concerns
about security and local regulations that constrain the prescription of addiction
pharmacotherapy would need to be addressed to facilitate such an expansion.(19)
The barriers cited varied by the type of setting. Respondents for jails displayed more
concerns about state or local regulations, security, and that community treatment programs
offer MAT. For prisons, security concerns, treatment philosophy (i.e. agency favors drug-
free treatment, and that MAT was inconsistent with their treatment philosophy) and the
availability of MAT from community programs emerged as issues. Drug courts cited
concerns about liability, lack of qualified medical staff, and the difficulties with
reimbursement. In probation and parole, the major issue that emerged was the availability of
MAT from community treatment programs.
Of the approximately five million adults under community supervision,(20) over 15% are
opioid-dependent, and alcohol use disorders are ubiquitous.(24,25) In the current study,
parole/probation respondents acknowledged opiate dependence in 17% of their clients and
alcohol dependence in 35%. So why is the use of MAT not more widespread in community
corrections? One can speculate that the availability of MAT in some communities,
inadequate information about the use of medication, negative attitudes toward MAT and a
preference for abstinence only approaches throughout criminal justice(23) together might
render agencies passive about ensuring adequate access to MAT.(19) Of note, agencies that
reported inadequate information as an important factor in current MAT practices were more
likely to be open to the possibility of introducing or expanding MAT than were those who
reported inadequate information as less of a factor. This finding may signal that those who
believe they have adequate knowledge in fact have a philosophical aversion based on
common misperceptions and myths about MAT rather than valid evidence.
Community correctional agencies do not perceive a need to take on this service delivery
role, as addiction pharmacotherapy could be obtained from local providers. Any expansion
in community correctional settings would thus require increased collaboration with
community MAT providers. Facilitating better linkages to community pharmacotherapy for
appropriate individuals under community correctional supervision might overcome other
issues, including security, liability, staffing or regulatory concerns. On this basis, the CJ-
DATS collaborative is in the process of designing a field study to increase knowledge,
attitudes and information about MAT and improve linkages to community MAT for opioid-
and alcohol-dependent clients on probation or parole supervision.
This study has several limitations. It is a convenience sample of criminal justice agencies
that have voluntarily associated with a multisite correctional drug abuse research initiative.
Volunteer bias would suggest that these systems may have better developed infrastructure,
attitudes, and readiness for MAT than would a representative sample of agencies. If so, the
infrastructure, attitudes, and readiness for MAT among other criminal justice agencies in the
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U.S. are likely to be less promising. For example, the “universe” of criminal justice agencies
probably has an even lower likelihood of introducing or expanding MAT for opiate
dependence in the next two years than the low-moderate likelihood (mean of two on a scale
from zero to five) in these partnering agencies. The survey items were developed based on
the expertise of our working group; despite their face validity, the psychometrics of the
survey items are unknown. Finally, the extent to which community corrections agencies
informally refer clients to community-based MAT was not determined by the survey.
Medication assisted treatment remains stigmatized and under-resourced in correctional
settings. Nonetheless, existing infrastructure to provide addiction pharmacotherapy for
pregnant women and detoxification provide a platform for incremental increases in MAT
implementation.(19) Efforts to expand access to appropriate pharmacotherapy assisted
treatment need to (1) address inadequate information, philosophical aversion and negative
attitudes about MAT through education and training about its benefits for the individual and
society; (2) improve linkage to MAT for opiate- and alcohol- dependent persons under
criminal justice supervision; and (3) target funding and resources toward the preferential use
of evidence-based treatment modalities such as MAT.
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